Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gonadotropin releasing hormone transdermal patch - Vyteris

X
Drug Profile

Gonadotropin releasing hormone transdermal patch - Vyteris

Alternative Names: Fertility hormone peptide Smart Patch™ transdermal patch; GnRH transdermal patch - Vyteris

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vyteris
  • Class Gonadotropins; Hormones; Infertility therapies; Oligopeptides
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Female infertility

Most Recent Events

  • 06 Jun 2013 Vyteris plans to sell transdermal drug delivery patents, subject to approval of US Bankruptcy Court
  • 06 Jun 2013 No development reported - Phase-II for Female infertility in USA (Transdermal)
  • 10 Nov 2010 Vyteris receives a grant under the US Government's Qualifying Therapeutics Discovery Project for the development of Smart Patch-based therapeutics in female infertility and diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top